CDK4 amplification was present in all but one dedifferentiated liposarcoma, and two potentially targetable mutations of the BRAF/MAPK pathway were detectable in undifferentiated (pleomorphic) sarcomas. This evidence concerns the gene CDK4 and sarcoma.